28.01.2014 • NewsICH BeneluxKrahn Chemie

Robbert Gorter Appointed Managing Director of ICH Benelux

Robbert Gorter, ICH Benelux
Robbert Gorter, ICH Benelux

Effective from February 1, 2014 Krahn Chemie appoints Robbert Gorter as managing director of its subsidiary ICH Benelux.

Robbert Gorter will join ICH Benelux to continue the ongoing growth of the company in the Benelux market. He will succeed Joost Boon, managing director and former owner of ICH, who will leave the company in the middle of this year.

Dr. Rolf Kuropka, managing director of the mother company Krahn Chemie, states: "Robbert Gorter has a deep technical and commercial knowledge of the chemical industry and brings a strong combination of leadership skills, team capabilities and experience in the chemical distribution industry to his new role. Working closely with the entire ICH team, he will ensure ICH´s continued commitment to its customers and supplying partners."

Robbert Gorter (47) is a graduate chemical engineer and also holds an MBA from the TiasNimbas / Bradford business school. He has held numerous positions with increasing responsibility within the international chemical industry and has a broad experience in sales and marketing, purchasing and new business development.

Company

Krahn Chemie

Mühlenhagen 35
20539 Hamburg
Germany

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read